PARIS -- The Swiss drug maker Roche Holding said Monday that it was offering about $43.7 billion to acquire the 44 percent of the biotechnology company Genentech that it does not already own.
Roche offered $89 in cash for each outstanding share of Genentech, a leading maker of cancer drugs. That represents a premium of 8.8 percent on Genentech's closing price Friday of $81.82.
Calling all HuffPost superfans!
Sign up for membership to become a founding member and help shape HuffPost's next chapter
